Peroxiredoxin i is overexpressed in oncocytic lesions of salivary glands

Journal of Oral Pathology and Medicine

Volumn 38, Issue 6, 2009, Pages 514-517

  Demasi, Ana P D ^a   Furuse, Cristiane ^a   Altemani, Albina ^b   Junqueira, José L C ^a   Oliveira, Paulo R G ^c   Araújo, Vera C ^a  

^a Faculdade de Odontologia e Centro de Pesquisas Sá O   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c Pathos Laboratory   (Brazil)

Author keywords

Immunohistochemistry; Mitochondria; Oncocytes; Peroxiredoxins; Salivary gland

Indexed keywords

PEROXIREDOXIN 1;

ARTICLE; CANCER CELL; CONTROLLED STUDY; EPITHELIUM CELL; GRANULAR CELL TUMOR; HUMAN; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; METAPLASIA; ONCOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SALIVARY GLAND TUMOR; WARTHIN TUMOR;

ADENOCARCINOMA; ADENOLYMPHOMA; ADENOMA, OXYPHILIC; ANTIOXIDANTS; BIOLOGICAL MARKERS; CARCINOMA, MUCOEPIDERMOID; FREE RADICAL SCAVENGERS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GRANULAR CELL TUMOR; HUMANS; HYDROGEN PEROXIDE; HYPERPLASIA; LYSOSOMES; METAPLASIA; MITOCHONDRIA; OXYPHIL CELLS; PEROXIREDOXINS; REACTIVE OXYGEN SPECIES; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS; THYROID GLAND;

EID: 67650757322     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00753.x     Document Type: Article

References (32)

1. Wakely PE JR. Oncocytic and oncocyte-like lesions of the head and neck. Ann Diagn Pathol 2008 12 : 222 30.
2. Tallini G. Oncocytic tumours. Virchows Arch 1998 433 : 5 12. (Pubitemid 28356470)
3. Asa SL. My approach to oncocytic tumours of the thyroid. J Clin Pathol 2004 57 : 225 32.
4. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000 408 : 239 47.
5. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007 39 : 44 84. (Pubitemid 44566469)
6. Demasi AP, Pereira GA, Netto LE. Cytosolic thioredoxin peroxidase I is essential for the antioxidant defense of yeast with dysfunctional mitochondria. FEBS Lett 2001 509 : 430 4.
7. Demasi AP, Pereira GA, Netto LE. Yeast oxidative stress response. Influences of cytosolic thioredoxin peroxidase I and of the mitochondrial functional state. FEBS J 2006 273 : 805 16.
8. Hofmann B, Hecht HJ, Flohe L. Peroxiredoxins. Biol Chem 2002 383 : 347 64.
9. Wood ZA, Schröder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 2003 28 : 32 40. (Pubitemid 36051004)
10. Kang SW, Rhee SG, Chang TS, Jeong W, Choi MH. 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. Trends Mol Med 2005 11 : 571 8.
11. Shintaku M, Honda T. Identification of oncocytic lesions of salivary glands by anti-mitochondrial immunohistochemistry. Histopathology 1997 31 : 408 11.
12. Rivollier A, Perrin-Cocon L, Luche S, et al. High expression of antioxidant proteins in dendritic cells: possible implications in atherosclerosis. Mol Cell Proteomics 2006 5 : 726 36.
13. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005 39 : 359 407. (Pubitemid 43011120)
14. Montone KT, Baloch ZW, Livolsi VA. The thyroid Hürthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review. Arch Pathol Lab Med 2008 132 : 1241 50.
15. Yeh JJ, Lunetta KL, Van Orsouw NJ, et al. Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene 2000 19 : 2060 6.
16. Savagner F, Franc B, Guyetant S, Rodien P, Reynier P, Malthiery Y. Defective mitochondrial ATP synthesis in oxyphilic thyroid tumors. J Clin Endocrinol Metab 2001 86 : 4920 5.
17. Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simões M. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am J Pathol 2002 160 : 1857 65.
18. Bonora E, Porcelli AM, Gasparre G, et al. Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res 2006 66 : 6087 96.
19. Gasparre G, Porcelli AM, Bonora E, et al. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci USA 2007 104 : 9001 6.
20. Simonnet H, Demont J, Pfeiffer K, et al. Mitochondrial complex I is deficient in renal oncocytomas. Carcinogenesis 2003 24 : 1461 6.
21. Heddi A, Faure-Vigny H, Wallace DC, Stepien G. Coordinate expression of nuclear and mitochondrial genes involved in energy production in carcinoma and oncocytoma. Biochim Biophys Acta 1996 1316 : 203 9.
22. Hartman P, Ponder R, Lo HH, et al. Mitochondrial oxidative stress can lead to nuclear hypermutability. Mech Ageing Dev 2004 125 : 417 20.
23. Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 1990 76 : 655 63.
24. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 100 : 57 70. (Pubitemid 30046295)
25. Neumann CA, Krause DS, Carman CV, et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 2003 424 : 561 5.
26. Huang ME, Rio AG, Nicolas A, Kolodner RD. A genomewide screen in Saccharomyces cerevisiae for genes that suppress the accumulation of mutations. Proc Natl Acad Sci USA 2003 100 : 11529 34.
27. Smith S, Hwang JY, Banerjee S, et al. Mutator genes for suppression of gross chromosomal rearrangements identified by a genome-wide screening in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 2004 101 : 9039 44.
28. Immenschuh S, Baumgart-Vogt E. Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal 2005 7 : 768 77.
29. Prochownik EV. Functional and physical communication between oncoproteins and tumor suppressors. Cell Mol Life Sci 2005 62 : 2438 59.
30. Hoshino I, Matsubara H, Akutsu Y, et al. Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients. Oncol Rep 2007 18 : 867 71.
31. Neumann CA, Fang Q. Are peroxiredoxins tumor suppressors? Curr Opin Pharmacol 2007 7 : 375 80.
32. Park CK, Kim JH, Moon MJ, et al. Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression. J Cancer Res Clin Oncol 2008 134 : 255 62.